|
|
|
Volumn 18, Issue 13 Suppl 10, 2004, Pages 32-38
|
|
Potential therapeutic applications of oblimersen in CLL.
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANTINEOPLASTIC AGENT;
ANTISENSE OLIGONUCLEOTIDE;
MESSENGER RNA;
MONOCLONAL ANTIBODY;
NUCLEOTIDE;
OBLIMERSEN;
PROTEIN BCL 2;
ANIMAL;
CHRONIC LYMPHATIC LEUKEMIA;
DOSE RESPONSE;
DRUG EFFECT;
GENE EXPRESSION REGULATION;
HUMAN;
METABOLISM;
PHASE 1 CLINICAL TRIAL;
PHASE 2 CLINICAL TRIAL;
PHASE 3 CLINICAL TRIAL;
REMISSION;
REVIEW;
SURVIVAL;
ANIMALS;
ANTIBODIES, MONOCLONAL;
ANTINEOPLASTIC AGENTS;
ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;
CLINICAL TRIALS, PHASE I;
CLINICAL TRIALS, PHASE II;
CLINICAL TRIALS, PHASE III;
DOSE-RESPONSE RELATIONSHIP, DRUG;
GENE EXPRESSION REGULATION, LEUKEMIC;
HUMANS;
LEUKEMIA, LYMPHOCYTIC, CHRONIC;
OLIGONUCLEOTIDES, ANTISENSE;
PROTO-ONCOGENE PROTEINS C-BCL-2;
REMISSION INDUCTION;
RNA, MESSENGER;
SURVIVAL ANALYSIS;
THIONUCLEOTIDES;
|
|
EID: 14144255254
PISSN: 08909091
EISSN: None
Source Type: Journal
DOI: None Document Type: Review |
|
Times cited : (10)
|
|
References (49)
|
